Attivissimo L A, Fetten J V, Kreis W
Don Monti Division of Medical Oncology, Department of Medicine, North Shore University Hospital, Manhasset, New York 11030, USA.
Am J Clin Oncol. 1996 Dec;19(6):581-3. doi: 10.1097/00000421-199612000-00010.
We evaluated the effectiveness of combination chemotherapy using estramustine and velban for metastatic prostate cancer. Patients with progressive metasatatic prostate cancer and rising prostate-specific antigen (PSA) values were evaluated between 1992 and 1994. All treatment was given on an outpatient basis. Vinblastine, 4 mg/m2 i.v., was given weekly for 6 weeks with a 2-week rest period. Estramustine, 10 mg/kg orally, was given in three divided doses for 6 weeks with a 2-week rest period between cycles. Of 15 patients, six (40%) had a response, in which a 25% decrease in PSA was associated with subjective improvement. There were no complete responses. Five partial responders had less pain. Median duration of response or time to progression was 9 months. Survival was 11.7 months for responders, 13.2 months for nonresponders. The combination of estramustine and velban is an effective therapy in progressive metastatic prostate cancer as measured by a decrease in PSA and improvement of symptoms.
我们评估了雌莫司汀和长春花碱联合化疗对转移性前列腺癌的疗效。1992年至1994年间，对患有进展性转移性前列腺癌且前列腺特异性抗原（PSA）值升高的患者进行了评估。所有治疗均在门诊进行。长春花碱，静脉注射4mg/m²，每周给药一次，共6周，休息2周。雌莫司汀，口服10mg/kg，分三次给药，共6周，周期之间休息2周。15例患者中，6例（40%）有反应，其中PSA下降25%与主观症状改善相关。无完全缓解病例。5例部分缓解者疼痛减轻。反应持续时间或疾病进展时间的中位数为9个月。反应者的生存期为11.7个月，无反应者为13.2个月。以PSA降低和症状改善衡量，雌莫司汀和长春花碱联合治疗对进展性转移性前列腺癌是一种有效的治疗方法。
